- Mirati Therapeutics Inc MRTX announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort of adagrasib combined with Merck & Co Inc's MRK Keytruda (pembrolizumab) in previously untreated metastatic lung cancer patients, harboring a KRASG12C mutation.
- Early data shows that a combination treatment demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate (ORR) of 49%, with a manageable safety profile.
- Related: Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month.
- Wall Street analysts called the early results encouraging, Reuters reported, but shares of Mirati were down more than 8%. More trial details will be presented on Wednesday.
- "We believe the data continue to support the regimen's differentiated positioning relative to standard of care and are far more favorable than that of Lumakras plus (immunotherapy)," a JP Morgan analyst said, referring to Amgen Inc's AMGN drug.
- Out of seven phase-two trial patients given the adagrasib combination, four (57%) had tumor shrinkage and a disease control rate of 100%.
- Price Action: MRTX shares traded 9.60% lower at $83.85 during pre-market trading on Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.